Learn ways to propel your drug development programs with proven bioanalytical strategies and techniques in our four new insight briefs:
Using 2 Advanced Techniques for Protein Bioanalysis
How are High Resolution Mass Spectrometry (HRMS) and Hybrid Immunoaffinity Liquid Chromatography-Mass Spectrometry (IA-LC-MS) driving unprecedented levels of precision and accuracy for protein bioanalysis? Hear from our LCMS Biologics and Biomarkers expert to learn more about how Q2
Solutions incorporates these technologies in our methodologies to drive solutions for customers’ drug development challenges. Immunogenicity Testing in Biologics R&D: What’s Your Strategy?
Immunogenicity testing can be a crucial component of your product’s development and success. Hear from our bioanalytical and ADME immunoassay services director to learn about the importance of immunogenicity assays in biologics R&D, as well as a key step in interpreting a therapy’s efficacy and safety. ADME Screening Services: Key Factors to Consider
Selecting the right partner for ADME services is a key component of an effective drug discovery partnership. Having delivered more than 76,000 in vitro screening assays in the last year, learn 7 key advantages of partnering with Q2
Solutions as your ADME screening service in our new insight brief.Bioanalysis: How to Adapt in an Evolving Market
Hear from our senior scientific director to discover how we employ a diverse set of capabilities, including ADME investigations of new small molecule drugs, biomarker analysis and immunogenicity risk assessments to challenge historical approaches and further bioanalysis for new drug therapies.
Having a partner that is staffed by scientists with extensive experience in advanced bioanalysis techniques and strategies, as well as thorough knowledge of regulatory guidelines and best practices, is a necessity in the rapidly growing healthcare landscape. Contact us
to learn more about how we employ a diverse set of capabilities, including ADME investigations of new small molecule drugs
, biomarker analysis
and immunogenicity risk assessments
to remain an industry leader and further bioanalysis for new drug therapies.